Home > Products > Novel inhibitors
Cat. No. Product name CAS No.
DCC1808 Displurigen

Inhibitor of ATPase activity of HSP70

96156-26-2
DCC1809 Distamycin A Hydrochloride

Antibiotic, specifically inhibiting the initiation of RNA synthesis, binding isohelically to the minor groove of B-DNA at A/T rich sites

6576-51-8
DCC1810 Distigmine Dibromide

Parasympathomimetic with longer duration of action

15876-67-2
DCC1811 Djt06001

Novel selective Factor Xa inhibitor, reducing thrombus formation with low risk of bleeding

1628182-40-0
DCC1812 Dk-1-150

Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line

DCC1813 Dk-1-166

Novel inducer of apoptotic cell death in TNBC cell lines without causing cytotoxicity in the normal mammary epithelial cell line

2204279-20-7
DCC1814 Dk-139

Inhibitor of NF-kappaB-mediated GROalpha expression, suppressing the TNFalpha-induced invasive capability of MDA-MB-231 human breast cancer cells

1426059-23-5
DCC1815 Dk-1-49

Novel autophagonizer, inducing autophagic cell death in apoptosis-defective cell line

853136-76-2
DCC1816 Dl0410

Novel acetylcholinesterase inhibitor, promoting synaptic function and neuronal survival, ameliorating cognitive deficits in SAMP8 mice via improved mitochondrial dynamics and increased activity of the NMDAR-CREB-BDNF pathway

DCC1817 D-lana-14

Novel potent anti-MRSA agent, disrupting biofilms with no resistance development, sensitizing rifampicin and tetracycline against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa

DCC1818 Dlc27-14

Specific protein disorder catalyzer of HIV-1 Nef

1360869-92-6
DCC1819 Dl-threo-dihydrosphingosine

Competitive inhibitor of both SPHK1 and SPHK2

2304-75-8
DCC1820 D-luciferin Phosphate Sodium Salt

Ultrasensitive bioluminogenic enzyme substrate

145613-12-3
DCC1821 D-lys(z)-pro-arg-pna

Chromogenic peptide substrate, being highly sensitive for the measurement of activated Protein C.

108963-69-5
DCC1822 Dma-cpptl

Prodrug of CPPTL, inducing apoptosis in a dose-dependent manner via the ROS/JNK pathway in acute myeloid leukemia

DCC1823 Dmako-20

Novel multi-target anticancer prodrug activated by the tumor specific CYP1B1 enzyme, potently inhibiting HCT-15, HCT-116 and K562 cells growth, showing moderate anti-proliferative activity towards MDA-MB-231, HepG2, PANC, Bel7402 and MGC803 cancer cells,

DCC1824 Dmako-5

Novel antineoplastic agent, exhibiting remarkable anticancer activity as well as excellent cellular selectivity

DCC1825 D-mannuronic Acid [6906-37-2]

Novel blocker of the TLR2 and TLR4 downstream signaling pathway, effectively inhibiting mRNA expression of MyD88 and p65, major subunit of nuclear factor-kappaB

6906-37-2
DCC1826 Dmb213

Novel non-nucleoside inhibitor of Zika viral RNA-dependent RNA polymerase (RdRp) enzymes

DCC1827 Dmcl1-2

Novel potent and selective PROTAC degrader of myeloid cell leukemia 1 (MCL1)

2351218-88-5
DCC1828 Dmnpe-caged Luciferin

Novel cell permeable caged Luciferin

223920-67-0
DCC1829 Dmocptl

Novel inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells

Page 1304 / Total 1557 FirstPrevNextLastGoto